Neurotechnology company Beacon Biosignals has secured $86m in a Series B funding round aimed at expanding its neurodiagnostic dataset and furthering the clinical use of AI-driven brain health biomarkers.
With this latest investment, the company’s total funding now exceeds $121m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The oversubscribed round was supported by a group of healthcare and technology investors, including Innoviva, Google Ventures (GV), S32, and Catalio Capital Management.
Logos Capital, Indicator Ventures, General Catalyst, and Casdin Capital also participated in the round.
Cleared by the US Food and Drug Administration (FDA), Beacon’s Waveband device differs from consumer wearables by directly recording the brain’s electrical activity (EEG) during both sleep and wakefulness.
This approach generates biosignal data that offer longitudinal insights into brain function across varied populations.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe data underpin the company’s brain activity foundation model, which has been trained on several hours of EEG recordings to identify early disease markers and forecast responses to treatment.
Beacon Biosignals CEO and co-founder Jacob Donoghue said: “Our mission is to make brain function measurable and actionable at scale.
“By training AI on millions of hours of real-world brain data, we’re beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated.”
Central to the company’s strategy is its Beacon Platform, which combines clinically validated EEG data with AI to produce quantitative brain function biomarkers through sleep analysis.
Beacon’s platform is currently used in research and development programmes with several biopharma firms as well as biotechs.
These partnerships make use of biomarkers derived from AI to support central nervous system drug development and marketing by delivering quantitative clinical endpoints, enabling the accurate selection of subjects.
The Series B financing follows the company’s recent purchase and integration of CleveMed’s home sleep-testing technology.
This addition expands the Beacon Platform to include measurements such as respiratory effort, airflow, and oxygen saturation.
